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INTRODUCTION
Advances in imaging techniques have led to the recognition of 
a transitional state of prostate cancer (PCa) in which the disease 
has limited metastasis beyond the prostate. In 1995, Hellman 
and Weichselbaum first identified and termed this entity as 
oligometastasis.1 Uppal, et al.2 suggested that metastatic disease 
between oligometastatic and polymetastatic patients have a 
separate regulation process, suggesting that the diseases men-
tioned above are distinct entities rather than different points 
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along a development continuum. Other researchers indicated 
that definitive directed treatments for PCa with limited metas-
tases may confer survival benefits for a select population.3
Androgen deprivation therapy (ADT) remains a cornerstone 
of systemic therapy through which to delay disease progression 
and to alleviate cancer-related symptoms in patients with met-
astatic hormone-sensitive prostate cancer (mHSPC).4 Many 
have regarded ADT as the treatment of choice for this popula-
tion; however, recent evidence-based guidelines recommend 
concurrent aggressive treatment options, including local ther-
apy or upfront chemotherapy.5 This recommendation is based 
on emerging data that suggest treatments targeted at the pri-
mary tumor and metastatic lesions in patients with limited me-
tastases may prevent or delay the need for palliative treatments 
and confer survival benefits.6
The risks of cerebrovascular disease (CVD) and PCa increase 
with age, and 16% of patients with ischemic stroke have been 
found to harbor PCa.7 While an association between PCa and 
CVD has not been elucidated, cancers have been shown to be 
associated with an increased risk of CVD through various bio-
logical mechanisms, including direct tumor effects or coagula-
tion disorders.8,9 Meanwhile, treatment decisions for PCa should 
be made based on a patient’s comorbidities and functional sta-
tus, which can affect overall survival (OS). Therefore, the risk of 
mortality from mHSPC and its treatment should be weighed 
carefully against the risk of mortality from existing significant 
comorbidities, such as CVD or cardiovascular disease, when 
making treatment decisions.10 Multiple comorbidities are fre-
quently noted at the time of biopsy-proven mHSPC. Unfortu-
nately, there is no consensus on which subgroup of patients for 
whom local treatment of the primary tumor may confer a sur-
vival benefit.
The primary endpoint of this study was the prognostic value 
of local treatment of primary tumors on OS outcomes in patients 
with de novo mHSPC. The secondary outcome was the con-
founding effect of comorbidities, such as CVD, at the time of 
mHSPC diagnosis on the prognostic impact of local treatment.
MATERIALS AND METHODS
Study population and data collection
Clinicopathological data for 1017 consecutive patients with new-
ly diagnosed mHSPC between August 2003 and November 2016 
were retrospectively collected from two institutions, Severance 
Hospital and Gangnam Severance Hospital (Yonsei University 
Health System). After stratifying patients by a history of CVD, 
baseline characteristics, including age, body mass index, pros-
tate-specific antigen (PSA) level, TNM stage, Gleason score, East-
ern Cooperative Oncology Group performance status, site of 
metastasis, preexisting medical conditions, such as hyperten-
sion and diabetes mellitus, and treatment types were reviewed. 
CVD was defined as previous radiological evidence of infarction 
on computed tomography brain scan identified by correspond-
ing focal neurological deficit. Patients were excluded from the 
analysis if they had incomplete clinical data (n=56), were lost 
during follow up (n=42), or had an unknown cause of death 
(n=40). In result, 879 (86.4%) patients were included in the fi-
nal analysis.
Patient survival and causes of death were investigated using 
the National Cancer Registry Database or institutional elec-
tronic medical records. The OS interval was defined as the time 
interval from PCa diagnosis to the date of all-cause death. Can-
cer-specific survival interval was defined as the time interval 
from PCa diagnosis to the date of death due to PCa. This retro-
spective study was approved by the Gangnam Severance Hos-
pital Institutional Ethics Committee (2017-0186-001), which 
waived the requirement for informed consent. All study proce-
dures complied with the principles of the 1946 Declaration of 
Helsinki and its 2008 update.
Treatments administered
Decisions on the type of initial treatment were determined based 
on physician discretion and patient preference. All patients 
received long-term ADT with or without local treatment [radi-
cal prostatectomy (RP) or radiation therapy (RT)]. RP was per-
formed by a retropubic or robotic approach, with the extent of 
pelvic lymph node dissection based on risk category. RT consist-
ed of intensity-modulated external beam RT, with a median RT 
dose of 7000 cGy (interquartile range: 7000–7000). Metastasis-
directed local treatments, including RT and/or metastasectomy, 
were offered for patients with symptomatic disease or those 
with a limited metastatic burden.
The diagnosis of castration-resistant PCa (CRPC) was based 
on consecutive rises in serum PSA levels, new symptom devel-
opment, or radiological progression despite a castrate serum 
testosterone level <50 ng/dL during ADT. Systemic treatments 
targeted against CRPC were performed according to contem-
porary guidelines.
Statistical analyses
The study groups were compared using the two-sided Mann–
Whitney U-test for the analysis of continuous variables and the 
chi-square test for the analysis of categorical variables. Variables 
considered potential predictors for multivariate modeling were 
selected by univariate analyses using the Cox proportional haz-
ards regression model.
To compare the OS outcomes of each patient group, Kaplan-
Meier survival analysis was performed according to prior CVD 
history and the type initial treatment (ADT alone vs. local treat-
ment). All statistical analyses were performed using IBM SPSS 
software (version 21.0; IBM Corporation, Armonk, NY, USA). 
Differences with a p value<0.05 were considered statistically 
significant.
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RESULTS
Baseline characteristics
Baseline features of the patients included in the analysis, strati-
fied by prior CVD history and the type initial treatment, are de-
scribed in Table 1. Of 879 patients, 660 (75.1%) underwent ADT 
alone, 90 (10.2%) underwent RT with ADT with or without me-
tastasis-directed therapy, and 129 (14.7%) underwent RP with 
ADT with or without metastasis-directed therapy.
Within all CVD history subgroups, patients who received ADT 
alone were older and exhibited higher Charlson Comorbidity 
Index (CCI) values than men who received local treatment. In 
the subgroup without a history of CVD, patients who received 
ADT alone had higher serum PSA levels than men who received 
local treatment. However, the two treatment subgroups were 
comparable in their distributions of all other classic PCa surviv-
al prognosticators. Moreover, there was no significant difference 
in the number or sites of metastasis between the ADT alone and 
ADT with local treatment groups (p=0.521, data not presented).
Systemic treatments administered following CRPC diagno-
sis are shown in Table 2. In the subgroup with CVD history, pa-
tients who received local treatment were more likely to have 
received a greater number of docetaxel cycles than men who re-
ceived ADT alone. However, there were no differences in the 
proportions of androgen receptor axis-targeted agents, caba-
zitaxel usage, enrollment in clinical trials, and secondary hor-
monal manipulations.
Survival outcomes
Table 3 and Fig. 1 show the OS outcomes of the overall cohort 
and the subgroups stratified according to prior CVD history and 
the type of initial treatment. In the overall group (Fig. 1A) and 
Table 1. Clinicopathological Characteristics of Patients with Metastatic Prostate Cancer Stratified by Cerebrovascular Disease History and Initial 
Treatment Category
Overall (n=879)
No CVD history (n=802) CVD history (n=77)
ADT alone
(n=615)
Local treatment
(n=187)
p value
ADT alone
(n=45)
Local treatment
(n=32)
p value
Age 66.5 (61.0–71.8) 70.0 (65.0–76.0) 67.0 (62.0–73.0) <0.001 74.0 (69.0–78.8) 68.0 (63.3–72.8) 0.001
Body mass index (kg/m2) 23.5 (21.5–25.2) 23.7 (21.8–25.6) 23.9 (21.8–25.5) 0.293 23.8 (22.2–26.3) 23.6 (21.4–25.6) 0.525
PSA (ng/dL) 69.2 (15.0–182.0) 123 (55.8–466.1) 37.6 (14.1–142.8) 0.004 123.7 (35.0–396.3) 63.2 (17.3–261.3) 0.359
Hypertension 299 (34.0) 201 (32.7) 64 (34.2) 0.757 22 (48.9) 11 (34.4) 0.516
Diabetes mellitus 151 (17.2) 104 (16.9) 27 (14.4) 0.565 13 (28.9) 5 (15.6) 0.485
Liver cirrhosis 14 (1.6) 9 (1.5) 2 (1.1) 0.545 2 (4.4) 1 (3.1) 0.468
T stage 0.246
≤T2 124 (14.1) 85 (13.8) 24 (12.8) 12 (26.7) 4 (12.5)
≥T3 755 (85.9) 530 (86.2) 163 (87.2) 33 (73.3) 28 (87.5)
N stage 0.495 0.145
N0 356 (40.5) 239 (38.9) 78 (41.7) 24 (53.3) 15 (46.9)
N1 523 (59.5) 376 (61.1) 109 (58.3) 21 (46.7) 17 (53.1)
Site of metastasis
Bone 605 (68.8) 431 (70.1) 123 (65.8) 0.154 31 (68.9) 20 (62.5) 0.485
Visceral 35 (4.0) 31 (5.0) 2 (1.1) 0.864 2 (4.4) 0 (0.0) 0.138
Lymph node 423 (48.1) 315 (51.2) 70 (37.4) 0.132 24 (53.3) 14 (43.8) 0.468
Number of metastasis 0.546 0.588
≤5 671 (76.3) 485 (78.9) 129 (69.0) 34 (75.6) 23 (71.9)
>5 208 (23.7) 130 (21.1) 58 (31.0) 11 (24.4) 9 (28.1)
Gleason score 0.051 0.145
≤7 174 (19.8) 103 (16.7) 43 (23.0) 18 (40.0) 10 (31.2)
≥8 705 (80.2) 512 (83.3) 144 (77.0) 27 (60.0) 22 (68.8)
CCI 0.039 0.017
≤1 577 (65.6) 429 (69.8) 115 (61.5) 12 (26.7) 21 (65.6)
≥2 302 (34.4) 186 (30.2) 72 (38.5) 33 (73.3) 11 (34.4)
ECOG PS <0.001 0.359
0 778 (88.5) 568 (92.4) 146 (78.1) 39 (86.7) 25 (78.1)
≥1 101 (11.5) 47 (7.6) 41 (21.9) 6 (13.3) 7 (21.9)
CVD, cerebrovascular disease; ADT, androgen-deprivation therapy; PSA, prostate-specific antigen; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Coopera-
tive Oncology Group performance status.
Data are presented as medians (interquartile range) and numbers (%).
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in patients without a history of CVD (Fig. 1B), men who received 
local treatment exhibited higher OS than men who received 
ADT alone (all p<0.001). However, the survival benefit of local 
treatment was not seen in the subgroup of patients with a his-
tory of CVD (p=0.324) (Fig. 1C). OS outcomes were compara-
ble between patients who received RP and RT (p=0.521, data 
not presented). The leading causes of death were attributable 
to PCa, followed by second primary malignancy and cardiovas-
cular disease (Table 3).
Predictors of survival
Univariate and multivariate models of predictors of overall mor-
tality (OM) are shown in Tables 4, 5, and 6. In the overall group 
and the subgroup without a history of CVD, multivariate anal-
ysis showed local treatment to be associated with a lower risk 
of OM, whereas this was not seen in the subgroup with a his-
tory of CVD.
In the overall group, serum PSA level, history of CVD, stage 
≥T3, and Gleason score ≥8 were significant prognosticators of 
Table 2. Systemic Treatments Administered Following Progression to Castration-Resistant Prostate Cancer
Overall (n=879)
No CVD history (n=802) CVD history (n=77)
ADT alone 
(n=615)
Local treatment 
(n=187)
p value
ADT alone 
(n=45)
Local treatment 
(n=32)
p value
Docetaxel 
N 214 (24.3) 151 (24.6) 34 (18.2) 0.155 10 (22.2) 19 (59.4) 0.001
No. cycles 4.0 (2.0–9.0) 5.0 (3.0–8.5) 3.0 (8.5–12.5) 0.484 4.0 (2.0–11.5) 5.0 (4.0–7.5) 0.587
ARAT agent use
Pre-chemotherapy 33 (3.8) 23 (3.7) 7 (3.7) 0.654 1 (2.2) 2 (6.3) 0.456
Abiraterone 12 (1.4) 8 (1.3) 2 (1.1) 0.819 0 (0.0) 2 (6.3) 0.170
Enzalutamide 21 (2.4) 15 (2.4) 5 (2.7) 0.801 1 (2.2) 0 (0.0) 0.912
Post-chemotherapy 101 (11.5) 55 (8.9) 29 (15.5) 0.644 5 (11.1) 12 (37.5) 0.564
Abiraterone 27 (3.1) 13 (2.1) 9 (4.8) 0.104 1 (2.2) 4 (12.5) 0.079
Enzalutamide 74 (8.4) 42 (6.8) 20 (10.7) 0.207 4 (8.9) 8 (25.0) 0.065
Cabazitaxel 8 (0.9) 6 (1.0) 2 (1.1) 0.954 0 (0.0) 0 (0.0) 0.556
Clinical trials 71 (8.1) 59 (9.6) 7 (3.7) 0.067 4 (8.9) 1 (3.1) 0.312
Secondary hormonal  
  manipulation
12 (1.4) 8 (1.3) 2 (1.1) 0.819 0 (0.0) 2 (6.3) 0.089
CVD, cerebrovascular disease; ADT, androgen-deprivation therapy; ARAT, androgen receptor-axis targeted.
Data are presented as medians (interquartile range) and numbers (%).
Table 3. Survival Outcomes in Patients with Metastatic Prostate Cancer Stratified according to Cerebrovascular Disease History and Initial Treatment 
Category
Overall (n=879)
No CVD history (n=802) CVD history (n=77)
ADT alone 
(n=615)
Local treatment 
(n=187)
p value
ADT alone 
(n=45)
Local treatment 
(n=32)
p value
OS, 5-year (%) 45.9 44.4 68.1 <0.001 32.1 39.1 0.324
No. all-cause deaths (n, %) 577 (65.6) 446 (72.5) 103 (55.1) <0.001 32 (71.1) 23 (71.9) 0.845
Cause of death (n, %)
PCa 493 (56.1) 370 (60.2) 71 (38.0) <0.001 30 (66.7) 22 (68.8) 0.847
Second primary malignancy 58 (6.6) 41 (6.7) 15 (8.0) 0.468 1 (2.2) 1 (3.1) 0.344
Cardiovascular disease 15 (1.7) 10 (1.6) 5 (2.7) 0.168 0 (0.0) 0 (0.0) NA
Cerebrovascular disease 4 (0.5) 2 (0.3) 2 (1.1) 0.453 0 (0.0) 0 (0.0) NA
Liver cirrhosis 3 (0.3) 1 (0.2) 2 (1.1) 0.135 0 (0.0) 0 (0.0) NA
Pneumonia 6 (0.6) 6 (1.0) 0 (0.0) 0.642 0 (0.0) 0 (0.0) NA
Renal disease 5 (0.6) 3 (0.5) 1 (0.5) 0.445 1 (2.2) 0 (0.0) 0.264
Self-harm 1 (0.1) 1 (0.2) 0 (0.0) 0.474 0 (0.0) 0 (0.0) NA
Other 19 (2.2) 12 (2.0) 7 (3.7) 0.344 0 (0.0) 0 (0.0) NA
Median OS period (mon) 38.0 (23.2–64.0) 34.0 (10.0–59.3) 34.0 (22.0–67.3) 0.512 30.0 (21.5–45.0) 36.0 (24.0–56.0) 0.565
Follow-up period (mon) 45.0 (26.0–76.0) 43.0 (24.0–73.0) 53.0 (28.0–75.0) 0.655 31.5 (20.0–58.5) 40.5 (26.3–60.8) 0.131
CVD, cerebrovascular disease; ADT, androgen-deprivation therapy; OS, overall survival; PCa, prostate cancer; NA, not available.
Data are presented as numbers (%) and medians (interquartile range).
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OM (Table 4). In the subgroup without a history of CVD, stage 
≥T3 and Gleason score ≥8 were associated with a higher risk of 
OM (Table 5). In the subgroup with a history of CVD, serum PSA 
level and CCI were associated with a higher risk of OM (Table 6).
Univariate and multivariate models of predictors for cancer-
specific mortality in the overall group are shown in Table 7. Age, 
stage ≥T3, Gleason score ≥8, and prior local treatment were sig-
nificant prognosticators (Table 7).
DISCUSSION
There has been a paradigm shift in considering local treatments 
targeted at both the primary tumor and metastatic lesions in 
patients with mHSPC and limited metastatic burden.6 However, 
there is no guideline on which subgroup of patients for whom 
such aggressive treatments may confer a survival benefit. We 
observed an OS benefit with local treatment of the primary tu-
mor in patients regardless of the metastatic burden. However, 
the survival benefit with local treatment was not seen in patients 
with a prior history of CVD. These findings suggest that comor-
bidities are crucial factors that affect the survival benefit of lo-
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Fig. 1. Kaplan-Meier curves showing overall survival in patients stratified by a history of cerebrovascular disease (CVD). (A) Overall group, (B) patients 
without a history of CVD, and (C) patients with a history of CVD. ADT, androgen-deprivation therapy.
Table 4. Cox Regression Models for Risk Factors associated with Overall Mortality in the Overall Cohort
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.012 1.001–1.023 0.032 1.009 0.995–1.022 0.201
Body mass index 0.971 0.942–1.001 0.061
PSA 1.000 1.000–1.001 <0.001 1.000 1.000–1.001 0.046
Hypertension (yes vs. no) 0.949 0.762–1.183 0.643
Diabetes mellitus (yes vs. no) 1.060 0.808–1.390 0.675
Liver cirrhosis (yes vs. no) 0.833 0.741–1.145 0.567
CVD (yes vs. no) 1.415 1.056–1.896 0.012 1.745 1.258–2.421 0.001
T Stage (≥T3 vs. ≤T2) 1.383 1.072–1.785 0.013 1.537 1.123–2.102 0.007
N stage (N1 vs. N0) 1.182 0.992–1.409 0.062
Site of metastasis
Bone 1 Reference
Visceral 1.005 0.961–1.051 0.554
Gleason score (≥8 vs. ≤7) 1.753 1.364–2.254 <0.001 1.801 1.325–2.447 <0.001
Treatment
ADT alone 1 Reference
Local treatment 0.664 0.540–0.817 <0.001 0.581 0.428–0.788 <0.001
CCI (≥2 vs. ≤1) 1.070 0.895–1.279 0.456
ECOG PS (≥1 vs. 0) 1.165 0.911–1.491 0.133
HR, hazards ratio; CI, confidence interval; PSA, prostate-specific antigen; CVD, cerebrovascular disease; ADT, androgen-deprivation therapy; CCI, Charlson co-
morbidity score; ECOG PS, Eastern Cooperative Oncology Group performance status.
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cal treatment in patients with mHSPC.
The biological definition of oligometastatic PCa remains de-
batable, and advances in imaging techniques are shifting the 
treatment paradigm of this disease entity. Various studies have 
proposed different definitions regarding the number and sites 
of metastatic lesions to define oligometastatic PCa based on 
oncological outcomes.11,12 The definition regarding the cut-off 
number of metastatic lesions is yet controversial, and for now, 
this disease entity should only be interpreted as a disease state 
between the presence of intravascular circulating tumor cells 
and disseminated metastasis.13,14 Existing studies regarding oligo-
metastatic PCa exclude patients with underlying comorbidi-
ties, such as CVD.15-19 Our study cohort included patients with 
initially diagnosed mHSPC regardless of the number of meta-
Table 5. Cox Regression Models for Risk Factors associated with Overall Mortality in Patients without a History of Cerebrovascular Disease
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.009 0.997–1.020 0.130
Body mass index 0.975 0.944–1.007 0.129
PSA 1.000 1.000–1.001 0.013 1.000 1.000–1.001 0.271
Hypertension (yes vs. no) 0.905 0.717–1.142 0.399
Diabetes mellitus (yes vs. no) 1.001 0.746–1.344 0.992
Liver cirrhosis (yes vs. no) 1.083 0.908–1.305 0.183
T Stage (≥T3 vs. ≤T2) 1.368 1.044–1.791 0.023 1.461 1.101–1.939 0.009
N stage (N1 vs. N0) 1.156 0.962–1.390 0.123
Site of metastasis
Bone 1 Reference
Visceral 1.103 0.971–1.225 0.485
Gleason score (≥8 vs. ≤7) 1.773 1.356–2.318 <0.001 1.635 1.243–2.151 <0.001
Treatment
ADT alone 1 Reference
Local treatment 0.626 0.499–0.786 <0.001 0.630 0.495–0.800 <0.001
CCI (≥2 vs. ≤1) 0.982 0.811–1.191 0.857
ECOG PS (≥1 vs. 0) 1.176 0.903–1.531 0.231
HR, hazards ratio; CI, confidence interval; PSA, prostate-specific antigen; ADT, androgen-deprivation therapy; CCI, Charlson comorbidity score; ECOG PS, Eastern 
Cooperative Oncology Group performance status.
Table 6. Cox Regression Models for Risk Factors associated with Overall Mortality in Patients with a History of Cerebrovascular Disease
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.038 1.001–1.075 0.044 1.026 0.989–1.064 0.174
Body mass index 0.933 0.842–1.034 0.184
PSA 1.000 1.000–1.001 0.007 1.000 1.000–1.001 0.029
Hypertension (yes vs. no) 1.447 0.723–2.897 0.297
Diabetes mellitus (yes vs. no) 1.383 0.653–2.928 0.397
Liver cirrhosis (yes vs. no) 1.106 0.776–1.486 0.329
T Stage (≥T3 vs. ≤T2) 1.699 0.761–3.789 0.196
N stage (N1 vs. N0) 1.468 0.804–2.678 0.211
Site of metastasis
Bone 1 Reference
Visceral 0.831 0.723–1.451 0.468
Gleason score (≥8 vs. ≤7) 1.869 0.900–3.884 0.094
Treatment
ADT alone 1 Reference
Local treatment 0.772 0.441–1.360 0.364
CCI (≥2 vs. ≤1) 2.006 1.099–3.663 0.023 2.024 1.075–3.910 0.029
ECOG PS (≥1 vs. 0) 1.101 0.547–2.213 0.788
HR, hazards ratio; CI, confidence interval; PSA, prostate-specific antigen; ADT, androgen-deprivation therapy; CCI, Charlson comorbidity score; ECOG PS, Eastern 
Cooperative Oncology Group performance status.
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static lesions and comorbidities, and there was no significant 
difference in metastatic burden between the ADT alone and 
ADT with local treatment groups. In an attempt to identify a sub-
set of patients who would benefit from local treatment of mH-
SPC, our study suggests that the number of metastatic lesions 
may not be the most significant indicator for predicting a sur-
vival benefit with local treatment.
Our study showed that CVD, followed by Gleason score, was 
the strongest prognosticator of OS. Several hypotheses can be 
offered. First, the detrimental effect of CVD on OS may have 
offset the beneficial effect of local treatment, in addition to well-
known prognostic factors, such as Gleason score and tumor 
stage. CVD is known to be significantly associated with surviv-
al, with a 0.15-year loss of life expectancy in the aged popula-
tion.20 It has been reported that the risk of thromboembolic dis-
ease increases as cancer stage increases.21 Babiker, et al.22 showed 
that the early release of prostasomes originating from PCa cells 
into the bloodstream evokes coagulation effects resulting in 
an increased risk of thromboembolism. Brain injury resulting 
from vascular pathology can also activate the coagulation cas-
cade, causing a state of hypercoagulability with the release of 
thromboplastin-like factors from the central nervous system.23 
In summary, a history of CVD, which indicates pathological he-
mostatic changes, may contribute to the disease course and OS 
outcomes. Future studies are warranted to identify the under-
lying pathophysiology of CVD in the PCa microenvironment. 
Second, the administration of continuous ADT may exacerbate 
CVD and its disease course. ADT increases coagulation disor-
ders that are related to a complex interplay of factors, including 
procoagulant factors released by tumor and/or host blood ves-
sels.22 Hypercoagulability is common in cancer patients, and 
hence, it is reasonable to consider that ADT serves as an aggra-
vator of CVD and inferior OS outcomes. Our results imply that 
comorbidities, especially CVD, are potential risk factors to be ac-
counted for when considering local treatments in addition to 
ADT for patients with mHSPC.
The strengths of our study are the inclusion of detailed clini-
copathologic data, treatment information, comorbidities, and 
performance status that were available from each patient. At 
the same time, some limitations exist. First, due to the observa-
tional nature of the study, the results should only be interpret-
ed within the limitation of a retrospective design. Diagnosis and 
ascertainment of CVD were dependent on chart reviews. While 
it is likely that there are undiagnosed cases, the use of medical 
records is a well-established method to consistently identify CVD 
outcomes within structured data. Second, the heterogeneity 
of the study cohort and the lack of a standard therapeutic ap-
proach, due to the strong patient and physician preference re-
garding the implementation of specific treatment modalities, 
were also limitations of this study. Nevertheless, we believe that 
such bias would be inherent in any retrospective study and may 
reflect the reality of clinical practice in which the application 
of sequential therapies for mHSPC is not standardized. Third, in 
the majority (87.3%) of patients, the presence of metastasis was 
determined from imaging studies and was not pathologically 
confirmed. Therefore, a proportion of our cohort might have 
harbored non-metastatic disease. Fourth, the possibility of un-
identified imbalance in baseline patients and tumor character-
Table 7. Cox Regression Models for Risk Factors associated with Cancer-Specific Mortality in the Overall Cohort
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Age 1.020 1.010–1.031 <0.001 1.015 1.003–1.027 0.016
Body mass index 0.964 0.937–0.992 0.013 0.976 0.946–1.006 0.110
PSA 1.000 1.000–1.001 <0.001 1.000 1.000–1.001 0.070
Hypertension (yes vs. no) 1.012 0.827–1.239 0.906
Diabetes mellitus (yes vs. no) 1.171 0.917–1.496 0.205
Liver cirrhosis (yes vs. no) 0.731 0.539–1.010 0.554
CVD (yes vs. no) 1.275 0.961–1.691 0.093
T Stage (≥T3 vs. ≤T2) 1.281 1.014–1.618 0.038 1.417 1.076–1.864 0.013
N stage (N1 vs. N0) 1.109 0.941–1.307 0.216
Site of metastasis
Bone 1 Reference
Visceral 1.093 0.912–1.321 0.564
Gleason score (≥8 vs. ≤7) 1.462 1.172–1.824 0.001 1.437 1.125–1.835 0.004
Treatment
ADT alone 1 Reference
Local treatment 0.635 0.521–0.774 <0.001 0.677 0.547–0.838 <0.001
CCI (≥2 vs. ≤1) 1.180 0.999–1.393 0.051
ECOG PS (≥1 vs. 0) 1.055 0.832–1.341 0.663
HR, hazards ratio; CI, confidence interval; PSA, prostate-specific antigen; CVD, cerebrovascular disease; ADT, androgen-deprivation therapy; CCI, Charlson co-
morbidity score; ECOG PS, Eastern Cooperative Oncology Group performance status.
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istics cannot be overlooked, along with the absence of a formal 
follow-up protocol, which may potentially confound the results 
of this study. Lastly, while cancer-specific survival may be con-
sidered as the most robust survival endpoint, we chose to use OS 
as the endpoint, since our study population included patients 
who were relatively older in age and had multiple comorbidities, 
in which 34% of the patients had CCI values ≥2. Indeed, as OS 
is affected by competing risks, we considered that OS may reli-
ably reflect the impact of CVD on survival in real-life cancer care.
A variety of factors influence outcomes in patient with CVD 
in the setting of underlying cancer. Local treatment with or with-
out metastasis-directed therapy may provide an OS advantage 
for de novo mHSPC patients without a history of CVD. While this 
association requires confirmation in a prospectively designed 
study, patients with PCa with a prior history of CVD may be of-
fered less aggressive treatment options.
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